Lake Forest-based startup ReVision Optics Inc. said in a regulatory filing last week that it raised $15 million.
ReVision makes the Raindrop, a replacement eye lens implanted through a small, laser-created opening in a patient’s cornea. It’s geared toward people 45 to 60 years old with presbyopia, a condition in which the eye loses its ability to focus close up as it ages.
The company didn’t disclose the investor or its plans on how it will use the proceeds in the Securities and Exchange Commission filing.
ReVision’s current investors include Domain Associates, a venture capital firm with offices in San Diego and Princeton, N.J., and InterWest Partners, with offices in Menlo Park and Dallas.
Raindrop, previously known as Presbylens and Vue+, is approved for sale in Europe. The Food and Drug Administration gave ReVision approval in late February to complete enrollment in a third-phase clinical trial for Raindrop.
—Vita Reed
